ライフサイエンスコーパス: antiandrogen therapy

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します

1 rogen receptor expression and sensitivity to antiandrogen therapy.

2 dditional loss of Trp53 causes resistance to antiandrogen therapy.

3 Survivin via AKT could mediate resistance to antiandrogen therapy.

4 upporting a novel mechanism of resistance to antiandrogen therapy.

5 ciated with the development of resistance to antiandrogen therapy.

6 cells resistant to androgen ablation and/or antiandrogen therapy.

7 tients treated with androgen ablation and/or antiandrogen therapy.

8 om a patient with disease progression during antiandrogen therapy.

9 approach for extending clinical responses to antiandrogen therapy.

10 eficiency was apparent in patients receiving antiandrogen therapy.

11 pment of resistance to androgen ablation and antiandrogen therapies.

12 undergo radiation therapy and receive either antiandrogen therapy (24 months of bicalutamide at a dos

13 Immediate antiandrogen therapy after radical prostatectomy and pel

14 mly assigned patients who had never received antiandrogen therapy and who had distant metastases from

15 de treatment is poorly responsive to further antiandrogen therapy, and paradoxically, rapid cycling b

16 that Survivin can mediate resistance to such antiandrogen therapies based on our assays.

17 Prostate cancer relapsing from antiandrogen therapies can exhibit variant histology wit

18 Although initially successful, antiandrogen therapy eventually fails and androgen deple

19 use the optimal timing of the institution of antiandrogen therapy for prostate cancer is controversia

20 strategy for sequencing between androgen and antiandrogen therapies in metastatic castration-resistan

21 It is hypothesized that administration of antiandrogen therapy in an intermittent, as opposed to c

22 Resistance to antiandrogen therapy in patients with metastatic prostat

23 eting of Survivin may enhance sensitivity to antiandrogen therapy in prostate cancer.

24 Antiandrogen therapy is only palliative, and chemotherap

25 on therapy, brachytherapy, and cryosurgery), antiandrogen therapy management of erectile dysfunction,

26 Nonsteroidal antiandrogen therapy may be discussed as an alternative,

27 in detection efficacy was present regarding antiandrogen therapy (P = 0.0783).

28 llular plasticity that, when challenged with antiandrogen therapy, promotes resistance through lineag

29 growth and survival and that treatment with antiandrogen therapy provides selective pressure and alt

30 rostate cancer has been transformed by novel antiandrogen therapies such as enzalutamide.

31 et for developing therapeutic agents for the antiandrogen therapy that almost always fails in the tre

32 iochemically motivated mathematical model of antiandrogen therapy that can be tested prospectively as

33 Resistance invariably develops to antiandrogen therapies used to treat newly diagnosed pro

34 which tends to be accelerated by the current antiandrogen therapy, we identify Peruvoside, a cardiac

35 The addition of 24 months of antiandrogen therapy with daily bicalutamide to salvage

36 Whether antiandrogen therapy with radiation therapy will further

37 were randomly assigned to receive immediate antiandrogen therapy, with either goserelin, a synthetic

WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。